Musings from The Power List: John Maher

John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors

1

John Maher's highlight was opening the AERIAL phase 1/2 trial for LEU011, an autologous CAR T-cell therapy for solid tumors.
2

The main bottleneck in cell and gene therapy is delivery, with issues in manufacturing complexity, cost, and logistics.
3

Progress in understanding therapy failures includes insights into resistance, antigen escape, and tumor microenvironment suppression.
4

Regulatory decisions impact the cost and access of therapies, shaping their development and delivery despite not controlling prices.
5

Successful cell and gene therapy programs must focus on scalable manufacturing, efficient delivery, and early engagement with stakeholders.